Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Living Cell Technologies ( (AU:1AI) ) has issued an announcement.
Algorae Pharmaceuticals Limited has applied to the ASX for quotation of 5,062,500 new ordinary fully paid shares under the code 1AI, with an issue date of March 5, 2026. The additional quoted securities, arising from the exercise or conversion of existing instruments, expand the company’s listed share base and may enhance liquidity for investors while modestly diluting existing shareholders’ holdings.
The move signals ongoing capital structuring activity as Algorae Pharmaceuticals advances its operations and funding plans within the biotech sector. By increasing the number of quoted securities, the company is positioning itself to support future development initiatives and maintain its presence in the public capital markets.
The most recent analyst rating on (AU:1AI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
More about Living Cell Technologies
Algorae Pharmaceuticals Limited is an Australia-based biotechnology company listed on the ASX under the code 1AI. The company operates in the pharmaceuticals sector, focusing on the development and commercialisation of drug candidates and related therapeutic technologies for healthcare markets.
YTD Price Performance: 14.29%
Average Trading Volume: 1,541,148
Technical Sentiment Signal: Hold
Current Market Cap: A$25.62M
For a thorough assessment of 1AI stock, go to TipRanks’ Stock Analysis page.